Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/5612

TDMS Study 89029-12 Pathology Tables

NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02

                    20MG(5MGX4)DMBA V 50 HZ/1G 20MG(5MGX4)DMBA V 50 HZ/5G 20MG(5MGX4)DMBA V 60 HZ/1G 20MG(5MGX4)DMBA 



       Facility:  Battelle Northwest

       Chemical CAS #:  EMF + DMBA

       Lock Date:  10/14/97

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 001    20 DMBA CONTROL
                               Include 003    50 HZ/1G 20 DMBA
                               Include 005    50 HZ/5G 20 DMBA
                               Include 004    60 HZ/1G 20 DMBA































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL      20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY                                                                                                                 
  Animals Initially In Study                         100          100          100          100                                     
  Early Deaths                                                                                                                      
    Natural Death                                      3            6            4            2                                      
    Moribund Sacrifice                                 3            7            4            3                                  
  Survivors                                                                                                                         
    Terminal Sacrifice                                93           86           92           94                                     
    Natural Death                                                   1                         1                                    
    Moribund Sacrifice                                 1                                                                            
  Animals Examined Microscopically                   100          100          100          100                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (100)        (100)        (100)        (100)                                  
      Angiectasis                                                                1 (1%)                                            
      Clear Cell Focus                                 1 (1%)                    3 (3%)       3 (3%)                                
      Fatty Change                                                  2 (2%)       1 (1%)       2 (2%)                                
      Hematopoietic Cell Proliferation                19 (19%)     12 (12%)     12 (12%)     22 (22%)                               
      Hepatodiaphragmatic Nodule                       1 (1%)                                                                       
      Necrosis                                                      1 (1%)       1 (1%)       2 (2%)                                
      Centrilobular, Necrosis                          1 (1%)       3 (3%)       1 (1%)       1 (1%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________

a  Number of animals examined microscopically at site and number of animals with lesion                                             





                                                             Page    2                                                              

NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL      20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (100)        (100)        (100)        (100)                                  
      Dilatation                                                                 1 (1%)                                
      Hyperplasia                                      4 (4%)                    3 (3%)       7 (7%)                                
      Inflammation, Chronic                                                      1 (1%)       2 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (100)        (100)        (100)        (100)                                  
      Foreign Body                                                               1 (1%)                                
      Inflammation, Chronic                            1 (1%)                    1 (1%)                                
      Thrombosis                                                                              1 (1%)
      Alveolar Epithelium, Hyperplasia                 6 (6%)                    5 (5%)       4 (4%)                                
      Alveolus, Infiltration Cellular, Histiocyte     11 (11%)      2 (2%)      15 (15%)      6 (6%)                               
   Trachea                                            (1)                                                                           
      Metaplasia, Squamous                             1 (100%)                                                                     
      Mineralization                                   1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (100)        (100)        (100)        (100)                                  
      Hydronephrosis                                                1 (1%)                    1 (1%)                                             
      Infarct                                                       1 (1%)                                                          
      Inflammation, Chronic Active                                               1 (1%)                                

a  Number of animals examined microscopically at site and number of animals with lesion                                             





                                                             Page    3                                                              

NTP Experiment-Test: 89029-12         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:02  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL      20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - CONT                                                                                                               
      Mineralization                                   2 (2%)                    1 (1%)       2 (2%)                                
      Nephropathy                                     15 (15%)     16 (16%)     10 (10%)     16 (16%)                               
      Pelvis, Inflammation, Suppurative                                          1 (1%)                                
                                                                                                                                    






































a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    4                                                              

                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------